Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine | MicrobiomeTrials
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2022-03-22Est. Completion: 2025-05-02
Enrollment target: 75 participants
Locations
Neurology and Neurodiagnostics of Alabama /ID# 242538, Hoover, Alabama, United States
Barrow Neurological Institute - Dignity Health St. Joseph's Hosp and Medical Ctr /ID# 241812, Phoenix, Arizona, United States
Arkansas Clinical Research /ID# 241789, Little Rock, Arkansas, United States
Hope Clinical Research /ID# 241772, Canoga Park, California, United States
Profound Research LLC /ID# 244084, Carlsbad, California, United States
Neuro Pain Medical Center /ID# 241992, Fresno, California, United States
Neurological Research Institute /ID# 242688, Santa Monica, California, United States
Neurology Offices of South Florida, PLLC /ID# 242693, Boca Raton, Florida, United States
Coastal Clinical Research Specialists /ID# 247992, Jacksonville Beach, Florida, United States
University of Miami /ID# 252230, Miami, Florida, United States
First Physicians Group - Waldemere /ID# 242861, Sarasota, Florida, United States
Kansas Institute of Research /ID# 241796, Overland Park, Kansas, United States
Duplicate_Ochsner Clinic Foundation /ID# 241803, Covington, Louisiana, United States
Other microbiome trials you might be interested in